Each 1 mg of denosumab-mobz (Boncresa) biosimilar injection administered

This code represents a biosimilar formulation of denosumab (reference product: Prolia or Xgeva), a RANK ligand inhibitor that reduces osteoclast-mediated bone resorption. Boncresa (denosumab-mobz) is dosed per milligram, requiring accurate unit reporting based on the administered dose. It is used in oncologic and metabolic bone disease contexts depending on the dose and indication.

Report this code for administration of denosumab-mobz when used for osteoporosis treatment or prevention of skeletal-related events in patients with bone metastases or multiple myeloma. Typical Prolia-equivalent dosing is 60 mg every 6 months; Xgeva-equivalent dosing is 120 mg monthly (with loading doses). Supporting documentation should include the specific mg dose administered, the indication, and confirmation that the biosimilar product (not the reference biologic) was dispensed.

• Unit reporting is critical: Bill in 1 mg increments — a 60 mg dose = 60 units; a 120 mg dose = 120 units. Undercoding units is a common error.
• Do not interchange with reference product codes (J0897 for denosumab); payers may deny claims if the billed code does not match the NDC on the claim — always verify the dispensed NDC maps to the biosimilar.
• Payer-specific biosimilar policies vary: Some payers require prior authorization or step therapy documentation confirming biosimilar use; confirm whether the administering setting (office vs. outpatient hospital) affects reimbursement methodology before submitting.